Author: Master2Dev4

26 Jan Test page

Posted at 15:30h in Uncategorized

Read More

23 Jan Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer

Posted at 15:10h in Homepage

Read More

22 Jan How Exsilio Therapeutics Is Expanding mRNA Drug Development

Posted at 15:09h in Homepage

Read More

07 Jan BioSpace’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends

Posted at 15:09h in Homepage

Read More

05 Jan Business of Biotech Podcast: Story Time With Tal Zaks, M.D.

Posted at 15:08h in Homepage

https://youtu.be/dKVEWflf4N8?si=y03INusamDiO2U8vhttps://youtu.be/sDi22UVLhE0?si=DEh1QWvnygD64eTT...

Read More

25 Jun Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases

Posted at 15:07h in Homepage

Read More